<DOC>
	<DOCNO>NCT00277329</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine activity , safety , tolerability XL999 give weekly patient non-small cell lung cancer ( NSCLC ) . XL999 small molecule inhibitor multiple kinase include VEGFR , PDGFR , FGFR , FLT-3 , Src , involve tumor cell growth , formation new blood vessel ( angiogenesis ) , metastasis .</brief_summary>
	<brief_title>Study XL999 Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Males female histologically confirm NSCLC Prior treatment platinum taxane contain regimen Stage IIIB malignant effusion , stage IV recurrent NSCLC amenable curative therapy ( either surgery radiation therapy ) Measurable disease accord Response Criteria Solid Tumors ( RECIST ) ECOG performance status 0 1 Life expectancy ≥3 month Adequate organ marrow function No malignancy within 5 year Signed informed consent Radiation ≥25 % bone marrow within 30 day XL999 treatment Use systemic anticancer therapy within 30 day XL999 treatment More 2 prior systemic cytotoxic chemotherapy regimens More 1 prior agent target VEGF EGFR ( eg , bevacizumab , erlotinib , gefitinib ) Subject recover ≤ grade 1 within 10 % baseline adverse event due medication administer &gt; 30 day study enrollment Uncontrolled and/or intercurrent illness History know brain metastasis , current spinal cord compression , carcinomatous meningitis Pregnant breastfeeding female Known HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>